Skip to main content
Top
Published in: Supportive Care in Cancer 10/2007

01-10-2007 | Letter to the Editor

In response to the article “The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline” (Bolderston et al. 2006)

Author: Kelly Nystedt

Published in: Supportive Care in Cancer | Issue 10/2007

Login to get access

Excerpt

I commend the authors for their work to develop evidence-based clinical practice guidelines for the management of radiation skin reactions, but I would like to clarify a statement that the British Columbia Cancer Agency’s (BCCA) guidelines (Care of Radiation Skin Reactions 2000) are “based on expert opinion and consensus rather than a systematic review of the evidence.” The process to develop the BCCA guidelines was published in 2005 [1] and closely parallels the cycle to develop evidence-based clinical practice guidelines as described by Browman et al. [2]. The guidelines were developed through a process that included (1) a review of the current literature, (2) a survey of current BCCA, national, and international clinical practice, and (3) consensus development among health care professionals in radiation therapy, radiation oncology and nursing of the BCCA’s regional cancer centers. The final document “Care of Radiation Skin Reactions” cites many of the same references as Bolderson et al. [3]. A more extensive review was completed but did not provide evidence to inform clinical practice guidelines. The BCCA guidelines initially written in 2000 were revised in 2002 and again in March 2006. A BCCA working group actively monitors the literature for relevant new evidence or skin care management guidelines. For the most up-to-date version, see http://​www.​bccancer.​bc.​ca/​HPI/​CancerManagement​Guidelines/​SupportiveCare/​RadiationSkinRea​ctions/​default.​htm. …
Literature
1.
go back to reference Nystedt KE, Hill JE, Mitchell AM, Goodwin F, Rowe LA, Wong FLW, Kind AL (2005) The standardization of radiation skin care in British Columbia: a collaborative approach. Oncol Nurs Forum 32(6):1199–1205PubMedCrossRef Nystedt KE, Hill JE, Mitchell AM, Goodwin F, Rowe LA, Wong FLW, Kind AL (2005) The standardization of radiation skin care in British Columbia: a collaborative approach. Oncol Nurs Forum 32(6):1199–1205PubMedCrossRef
2.
go back to reference Browman GP, Levine MN, Mohide EA, Hayward RS, Pritchard KI, Gafne A et al (1995) The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation. J Clin Oncol 13:502–512PubMed Browman GP, Levine MN, Mohide EA, Hayward RS, Pritchard KI, Gafne A et al (1995) The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation. J Clin Oncol 13:502–512PubMed
3.
go back to reference Bolderston A, Lloyd NS, Wong RKS, Holden L, Robb-Blenderman L, the Supportive Care Guidelines Group of Cancer Care Ontario Program in Evidence-based Care (2006) The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer 14(8):802–817PubMedCrossRef Bolderston A, Lloyd NS, Wong RKS, Holden L, Robb-Blenderman L, the Supportive Care Guidelines Group of Cancer Care Ontario Program in Evidence-based Care (2006) The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer 14(8):802–817PubMedCrossRef
Metadata
Title
In response to the article “The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline” (Bolderston et al. 2006)
Author
Kelly Nystedt
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 10/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0249-4

Other articles of this Issue 10/2007

Supportive Care in Cancer 10/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine